Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SCFSkp2-IN-2 是一种 Skp2抑制剂,其 KD 为 28.77 μM。AAA-237 诱导 NSCLC 细胞凋亡 (apoptosis),显示出抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 398 | 现货 | ||
10 mg | ¥ 657 | 现货 | ||
25 mg | ¥ 1,320 | 现货 | ||
50 mg | ¥ 2,150 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
500 mg | ¥ 7,880 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 441 | 现货 |
产品描述 | SCFSkp2-IN-2, a Skp2 inhibitor, exhibits a dissociation constant (K_D) of 28.77 μM. It demonstrates antitumor activities by inducing apoptosis in non-small cell lung cancer (NSCLC) cells. |
靶点活性 | Skp2:28.77 μM(kd) |
体外活性 |
SCFSkp2-IN-2 (Compound AAA-237) (0.3-3 μM ; 24-72 h) binds directly to Skp2, leading to degradation of Skp2 by the proteasome.AAA-237 has no significant effect on Skp2 mRNA expression, but has a time-dependent inhibitory effect on Skp2 protein expression in NSCLC cells.[1] SCFSkp2-IN-2 (0.3-3 μM ; 24-72 h) inhibited the proliferation of A549 and H1299 cells in a dose- and time-dependent manner.[1] SCFSkp2-IN-2 (0.3-3 μM ; 24-72 h) blocks the cell cycle at the G0/G1 checkpoint by regulating the Skp2-Cip/Kip and PI3K/Akt-FOXO1 signaling pathways.[1] SCFSkp2-IN-2 (0.3-3 μM ; 24-72 h) induces apoptosis in A549 and H1299 cells in a dose- and time-dependent manner.[1] SCFSkp2-IN-2 (0.3 μM ; 1-7 days) induces NSCLC cell senescence.[1] |
体内活性 | SCFSkp2-IN-2 (Compound AAA-237) (15 or 45 mg/kg ; i.p. ; daily for 14 days) showed antitumor activity in a mouse model of lung cancer A549 xenograft.[1] |
分子量 | 312.37 |
分子式 | C17H20N4O2 |
CAS No. | 1375060-02-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 112.5 mg/mL (360.2 mM ), Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.2013 mL | 16.0067 mL | 32.0133 mL | 80.0333 mL |
5 mM | 0.6403 mL | 3.2013 mL | 6.4027 mL | 16.0067 mL | |
10 mM | 0.3201 mL | 1.6007 mL | 3.2013 mL | 8.0033 mL | |
20 mM | 0.1601 mL | 0.8003 mL | 1.6007 mL | 4.0017 mL | |
50 mM | 0.064 mL | 0.3201 mL | 0.6403 mL | 1.6007 mL | |
100 mM | 0.032 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SCFSkp2-IN-2 1375060-02-8 Apoptosis Ubiquitination E1/E2/E3 Enzyme SCFSkp2IN2 Inhibitor inhibitor inhibit